LionelDavidLewisMD

Internal Medicine • Lebanon, NH

Professor, Medicine, Geisel School of Medicine

Join to view full profile

Are you Dr. Lewis?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 16 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1 Medical Center Dr
Section of Clinical Pharmacology DHMC
Lebanon, NH 03756
Phone+1 603-650-5000

Summary

Dr. Lionel Lewis, MD is an internist in Lebanon, New Hampshire. He is currently licensed to practice medicine in New Hampshire. He is affiliated with Dartmouth-Hitchcock Medical Center and is a Professor at Geisel School of Medicine.

Education & Training

The University of Wales College of MedicineClass of 1988

Certifications & Licensure

NH State Medical License 1993 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Docetaxel in Treating Patients With Solid Tumors Start of enrollment: 1998 Sep 01
Completed
Phase 2
Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Oct 01
Completed
Phase 1
Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Oct 01
Completed
Phase 1
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Withdrawn
Phase 3
Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871 Start of enrollment: 2008 Oct 01
Completed
A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients Start of enrollment: 2013 Feb 27
Completed
Phase 1
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
Completed
Phase 1
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2016 Aug 01
Withdrawn
Phase 1
A Study of BNC105P Combined With Ibrutinib Start of enrollment: 2018 Mar 09
Completed
Phase 1
Pan Tumor Rollover Study Start of enrollment: 2019 Aug 09
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma.
Crismita Dmello, Andrew Brenner, David Piccioni, Patrick Y Wen, Jan Drappatz
Neuro-Oncology Advances. 2024-12-14
Implementation of a pharmacist-guided pharmacogenomics dosing service at a rural NCI-designated comprehensive cancer center.
Jenna K Green, Laura J Hackett, Donald C Green, Sophie J Deharvengt, Gabriel A Brooks
Journal of Oncology Pharmacy Practice. 2024-09-04
Characterization of Stealth Liposome-Based Nanoparticles Encapsulating the ACAT1/SOAT1 Inhibitor F26: Efficacy and Toxicity Studies In Vitro and in Wild-Type Mice.
Junghoon Lee, Adrianna L De La Torre, Felix L Rawlinson, Dylan B Ness, Lionel D Lewis
International Journal of Molecular Sciences. 2024-08-23

Press Mentions

Issue HighlightsAugust 24th, 2020
Drug Combination More Effective in Metastatic Renal Cell CancerJuly 26th, 2017

Grant Support

Protocol Review And Monitoring SystemNational Cancer Institute2009–2012
Clinical Pharmacology Shared ResourceNational Cancer Institute2009–2012
Toxicology, Pathology And Biodistribution Core (Tpb Core)National Cancer Institute2011
Clinical MolecularNational Cancer Institute2004–2008